Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

For Myopathy Basic Diagnostic Rules Hold

  |  Issue: November 2010  |  

“This is an exciting time for autoimmune disease therapeutics, including myositis,” Dr. Oddis concluded. “We’ve got a lot of potential biologic and nonbiologic targets—but we always, always, always have to temper our enthusiasm with a respect for these agents and their downstream effects that we may appreciate down the road.”

Gretchen Henkel is a medical journalist based in California.

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    New Tools for Myositis Diagnosis, Classification & Management

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…